Company news

BioVie Inc. news in 2021

BioVie Inc.'s news releases, calls and decks from 2021, newest first.

View company

BioVie Announces Partnership with the American Liver Foundation

December 8, 2021

BioVie Secures Up to a $25.0 Million Debt Facility with Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P.

November 30, 2021

BioVie Announces the Appointment of a New Chief Medical Officer

October 31, 2021

BioVie Announces FDA Authorization to Initiate Phase 2 Trials Assessing NE3107’s Pro-motoric Activity in Parkinson’s Disease

October 25, 2021

BioVie Inc. Announces Closing of Public Offering of Common Stock

August 10, 2021

BioVie Inc. Announces Pricing of Public Offering of Common Stock

August 7, 2021

BioVie Inc. Announces Proposed Public Offering of Common Stock

August 5, 2021

BioVie Announces First Patient Enrolled in Phase 3 Study of NE3107 in Alzheimer’s Disease

August 4, 2021

BioVie Presents Data Supporting use of NE3107 in the Treatment of Alzheimer’s Disease at 2021 Alzheimer’s Association International Conference

July 26, 2021

BioVie Announces First Patient Enrolled in BIV201 Phase 2b Clinical Trial for Ascites

June 23, 2021

BioVie Receives FDA Guidance for Phase 3 Clinical Trial of BIV201 in HRS-AKI

June 22, 2021

BioVie Announces Closing of Acquisition of BioPharma Assets from Privately Held NeurMedix

June 10, 2021

BioVie Announces Amended Terms for Asset Acquisition from Privately Held NeurMedix

May 9, 2021

BioVie Acquires Biopharma Assets from Privately Held NeurMedix

April 26, 2021

BioVie Commences Patient Screening in Phase 2 Clinical Trial

March 8, 2021

Decks in 2021